Print this page

Glaucoma Research: A Year of Progress

Dr. Simon Skalicky & Clin Assoc Prof Andrew White | 28 February 2018
Greater knowledge of disease risk factors, new approaches to detection and monitoring, and innovative treatments are positively impacting glaucoma outcomes.

Over the past year we’ve seen a continued shift towards surgical/laser management of glaucoma, coupled with depot preparation medication trials rather than drop therapy. A major prospective trial looking at the efficacy of depot bimatoprost intracamerally has just finished recruiting (ARTEMIS 1) and two more are still underway (ARTEMIS 2 and ATHENA). Other similar trials are underway as well as assessment of an ocular ring releasing bimatoprost.1,2

Should We Add Vitamin B3 to the Water?

The paper with the biggest potential therapeutic impact this year described the potentially protective role of Vitamin B3 in glaucoma. A team from the Jackson Labs in the US fed vitamin B3 to mice prone to ocular hypertension, resulting in a significant reduction in the risk of ganglion cell death. This effect was even greater than targeted gene therapy treating the proposed metabolic/inflammatory pathway implicated in the disease process.3 Small scale clinical trials have already started. Much like the findings from the Nurses Health Study and nitrates, there seems to be an increasing role for dietary and nutritional supplementation in preventing glaucoma and/or halting progression.4

Minimally Invasive Glaucoma Surgery

Undoubtedly in 2017, glaucoma clinical practice focused on minimally invasive glaucoma surgery (MIGS).

MIGS represents a broad group of small surgical devices characterised by minimal conjunctival dissection, short operating times, rapid recovery and a good safety profile. This is a rapidly expanding field with trans-trabecular devices (eg iStent, Glaukos), increasingly performed in conjunction with cataract surgery.

Other devices are available, with a growing body of supportive data, such as the Cypass (Alcon), which creates a cyclodialysis cleft and drains to the suprachoroidal space and the Hydrus microstent (Ivantis), a fenestrated curved tube that enters, passes through and dilates Schlemm’s canal.

Currently, Medicare restricts the use of these devices to only at the time of cataract surgery, although work is underway to expand the availability for the procedure to a wider body of glaucoma patients, and potentially allow stand-alone MIGS procedures.

There is still a scarcity of robust MIGS scientific data. A meta-analysis of all MIGS papers released up until 2016 found that while overall safety data from MIGS is reassuring, good head-to-head random clinical trials comparing MIGS devices to one another or to traditional glaucoma surgery is lacking.5 As clinicians in this field, it is imperative we collect quality local data that evaluates MIGS in real-world clinical practice, and audit through communal software platforms such as the Save Sight Registry.*

Hydrus was compared head-to-head with selective laser trabeculoplasty (SLT) in a small (n=56) case series. Hydrus resulted in a greater reduction in medication dependence than SLT at 12 months.6

Filtration Surgery

Glaucoma filtration surgery (eg. trabeculectomy, tube surgery) involves creating an aqueous drainage pathway from inside the eye to the subconjunctival space. Some preliminary results have been released for the Primary Trab vs. Tube Study (PTVT) that attempts to settle the question as to whether a primary drainage tube may be better than trabeculectomy as a first surgical procedure for glaucoma. In a word, no.7,8 IOP control was better in the trabeculectomy group, especially in those with lower starting IOP. The complication rate was similar despite more early complications/interventions in the trabeculectomy group.

The Xen Gel Implant (Allergan) is a soft collagen implant that is inserted, ab interno, from the anterior chamber into the subconjunctival space creating a bleb. In many ways it is more similar to traditional filtration surgery than to other MIGS devices. It is increasingly used as an alternative to trabeculectomy, although quality head-to-head studies comparing Xen to trabeculectomy are few.

The Xen was shown to be effective in uveitic glaucoma, despite the potential for sight-threatening complications of hypotony, bleb infection9 or suprachoroidal haemorrhage10 (ie similar complications to a trabeculectomy).

Lasers in Glaucoma

The efficacy and safety of SLT in the treatment of open angle glaucoma (OAG) continues to be supported by the literature. SLT was evaluated in Afro-Carribeans with primary OAG (POAG) and found to have a 12 month success rate of 78 per cent.11 In Belgium, SLT was evaluated as replacement therapy for medically controlled OAG; it was able to completely replace medical therapy in 77 per cent of eyes after 18 months12 and improved treatment related quality-of-life (QoL)13 with similar efficacy between phakic and pseudophakic eyes.14 However, when 24-hour IOP rhythm was evaluated by the contact lens sensor Triggerfish, SLT was not shown to alter the amplitude or pattern of the IOP rhythm.15

Angle Closure and Glaucoma

Angle closure is frequently missed, both among patients referred for cataract surgery who are often dilated without prior gonioscopy, and among patients with POAG who can develop phacomorphic angle closure with age. Two studies from Canada elegantly demonstrated this; of patients referred for cataract surgery, 1.5 per cent were found to have undetected narrow angles,16 and one in 11 patients, with a diagnosis of OAG referred to a tertiary glaucoma centre, were found to in fact have angle closure.17

Dysphotopsia is a rare but debilitating complication of laser peripheral iridotomy (LPI). Previous data suggested the frequency of this can be reduced by temporal placement of the LPI.18 However, a larger (n=595) Indian/US RCT found that location, LPI size, and amount of laser energy used did not affect the frequency of dysphotopsia reported.19

Another large Indian study confirmed that LPI hastens the development of cataract.20 These findings support the landmark EAGLE study that compared early clear lens extraction (CLE) to laser iridotomy in the management of primary angle closure glaucoma (PACG). CLE showed greater efficacy and was more cost-effective than laser iridotomy.21

Externally applied micropulse cyclophotocoagulation (M-CPC) is an alternative mode of laser delivery to continuous wave cyclophotocoagulation (CW-CPC). Micropulse has a high post-treatment inflammation rate (46 per cent after three months) and a similar but potentially lower complication profile than CW-CPC.22 More head-to-head studies are required comparing micropulse to continuous wavelength and to endoscopic CPC to better elucidate this rapidly developing technology.

Monitoring and Detection

We have yet to improve the 50 per cent undiagnosed glaucoma rate in Australia. However, new advances in diagnostic technology, a greater drive for optometry-led detection, and an emphasis on first-degree relative screening such as through the TARRGET study may improve the detection rate.

Australian-developed tablet-based perimetry has the potential to revolutionise glaucomatous monitoring, allowing home or waiting-room self-screening for glaucoma. It is easy to use and sensitive to glaucomatous progression.23,24

Three separate studies have confirmed the importance of central (eg 10-2) visual fields in glaucoma diagnosis to complement 24-2 fields; the latter might miss early glaucomatous defects. This trend persisted irrespective of the type of field machine used.25-27 Furthermore 10-2 changes had a greater impact on vision-related quality of life (QoL) than 24-2 changes.28

The frequency of monitoring for glaucoma patients continues to vex strained clinics. One study found twice yearly visual field testing had similar sensitivity to thrice yearly for detecting glaucoma progression, provided two quality baseline tests were available for reference.29 These findings support the UK Glaucoma Treatment Study, in which a few early visual fields established a firm baseline; this allowed sensitive detection despite greater intervals between later field tests.30

OCT-angiography (OCT-A) continues to be explored in glaucoma. Adding to vascular loss previously described at the optic nerve head, new studies have found macular vascular density declines in glaucoma.31,32 However this finding was not consistent; one study found the macular vessels were spared in glaucoma.33 In addition, the diagnostic sensitivity of OCT-A is lower than traditional OCT metrics (RNFL and MGC complex thickness).33

One drawback of OCT analysis glaucoma is a floor effect of the peripapillary RNFL (sensitivity is lost in advanced disease). In agreement with prior studies, the ganglion cell inner plexiform layer metric was again shown to be more sensitive for advanced glaucoma than the peripapillary RNFL and continued to demonstrate progression once the RNFL had reached its floor effect.34,35

More data has supported the water drinking test, finding IOP spikes induced by the water-imbibed challenge were predictive of future glaucomatous progression.36

The Genetics of Glaucoma

The last few years have seen an explosion of genes identified in glaucoma pathogenesis. Novel loci include: for POAG (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and pseudoexfoliation syndrome glaucoma (CACNA1A).37 There are so many genes implicated that work is beginning to move towards better phenotyping of glaucoma for targeted gene studies, and studies looking at the functionality of these genes and interactions with each other (ie. is it combinations of gene anomalies rather than a single gene that is causative?). Stay tuned.

Health, Socioeconomic and Lifestyle Factors

Smoking was the smoking gun for glaucoma in 2017. A Spanish cohort population study of 16,797 participants over 8.5 years demonstrated a direct association between current smokers and glaucoma incidence, and the risk increased with number of pack-years.38

Additionally, a retrospective study looking at risk factors for rapid glaucoma progression showed rapid progressors were older, had significantly lower baseline IOP and central corneal thickness, and significantly higher rates of cardiovascular disease and hypotension.39 Further prospective study needs to be done to better understand the pathophysiology behind this finding.

A Taiwanese study evaluated the influence of different socioeconomic factors on vision-related quality of life in glaucoma. A lower education – but not income – affected QoL detrimentally, suggesting the importance of additional counselling for patients with a lower educational level to help them cope with the disease.40

Other Medical Therapies

Drug development for new glaucoma therapies has been slow but continues.

Rhopressa (Netarsudil 0.02 per cent) is a once daily topical agent with two mechanisms of action and two targets. Rhopressa targets rho-kinase (ROCK) and a norepinephrine transporter (NET). Trial results (ROCKET1-4) yet to be published seem promising. The most common side effect was mild redness of the eyes.

A combination product, Roclatan, is a once daily, combination of netarsudil 0.02 per cent + latanoprost 0.005 per cent made by the same company (Aerie Pharmaceuticals). Initial results from two trials (Mercury 1 and 2) also seem promising.

A new pathway for treatment was discovered this year that may also show promise. The angiopoietin-Tie2 system is crucial in the development and maintenance of Schlemm’s canal and hence IOP control. Antibody mediated activation of Tie2 resulted in an increase in drainage apparatus in Schlemm’s canal when injected in mice. Further development of this pathway may lead to a new IOP lowering agent in the future.37


As clinical and laboratory science marches forward, we must stay nimble in our approach to clinical practice, and translate the new knowledge into better, more efficient and more inclusive glaucoma care delivery to all patients.

Clinical Associate Professor Andrew White is a clinician scientist ophthalmologist at Westmead Hospital with a subspecialty interest in glaucoma. He is a Clinical Senior Lecturer and has research affiliations with the University of Sydney at both the Save Sight Institute and Westmead Millennium Institute where he has an active laboratory. Clin.Assoc. Prof. White has multiple peer-reviewed scientific publications and published conference abstracts. He is a regular invited speaker at overseas conferences and is actively involved in training medical students, registrars and fellows in cataract and glaucoma. He also lectures optometrists and optometry students in Glaucoma.

Dr. Simon Skalicky, FRANZCO, PhD, BSc (Med), MPhil, MMed, MBBS (Hons 1) is a glaucoma subspecialist in Melbourne. He is a Clinical Senior Lecturer at the University of Sydney and University of Melbourne. Dr Skalicky is widely published and actively involved in teaching. He is a federal Councillor for Glaucoma Australia and Associate Advisory Board member for the World Glaucoma Association. Dr. Skalicky specialises in glaucoma and cataract surgery.

*To find out more about participating in the Save Sight Registrar Glaucoma module visit: https://frbresearch.org/au

TARRGET Study Aims to Improve Glaucoma Detection

Professor David Mackey

The Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG) provides genetic testing for glaucoma patients and relatives. We know that genetics plays a major role in the risk for glaucoma and several genes of high and moderate risk have been identified, however these account for just 5 per cent of glaucoma cases at present. Pending the discovery of the other glaucoma genes, the major ‘genetics’ tool in identifying individuals with a high risk of glaucoma is a known family history of glaucoma.

With this in mind, over the past 20 years, Glaucoma Australia has emphasised the importance of a family history and the need for relatives of people diagnosed with glaucoma to get tested – early diagnosis and treatment prevents glaucoma blindness.

In Australia, the TARRGET study (Targeting at risk relatives of glaucoma patients for early diagnosis and treatment) has been initiated to evaluate a family screening program for glaucoma. High risk close relatives of severely affected glaucoma patients will be referred to have an appropriate eye examination and genetic testing for glaucoma.

In city areas of Perth, Adelaide, Sydney, and Tasmania, first degree relatives will be referred to their local eye care provider and their uptake and outcomes of screening examinations will be monitored. Relatives in 16 rural and remote locations in Western Australia, will be examined using the facilities of the recently launched Lions Outback Vision Van. The use of new optic nerve screening modalities for glaucoma using Retinal Nerve Fibre Analysis with OCT imaging will also be evaluated.

The main outcome measure from the TARRGET study will be the prevalence of undiagnosed glaucoma in those who participate. Secondary measures include participation rates of index cases and participation rates in first degree relatives as well as a comparison of uptake in rural areas where the ophthalmic examination will be provided at no charge in regional centres. Participants will also be invited to provide a blood sample for DNA testing for myocilin and cascade genetic screening in the future.

Funded by the National Health and Medical Research Council (NHMRC), the TARRGET study is a partnership project between the University of Western Australia/Lions Eye Institute, Flinders University of South Australia, the University of Tasmania and Sydney Eye Hospital with Glaucoma Australia and WA Country Health Service (Department of Health WA). 

Professor David A Mackey is the Managing Director of the Lions Eye Institute and Professor of Ophthalmology and Director of the Centre for Ophthalmology and Vision Science at the University of Western Australia. Professor Mackey has achieved international recognition as a genetic ophthalmologist. His original research into the genetics of glaucoma and in the fields of optic atrophy and congenital cataract has received continued research funding support for the past two decades.

1. Brandt JD, Sall K, DuBiner H, et al. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study. Ophthalmology. 2016; 123: 1685-94.
2. Brandt J, Dubiner H, Benza R, et al. Reduction in IOP from a sustained-release bimatoprost ring: pooled results from 2 open-label extension (OLE) studies. The 27th Annual AGS Meeting. Coronado, CA 2017.
3. Williams PA, Harder JM, Foxworth NE, et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017; 355: 756-60.
4. Kang JH, Willett WC, Rosner BA, Buys E, Wiggs JL and Pasquale LR. Association of Dietary Nitrate Intake With Primary Open-Angle Glaucoma: A Prospective Analysis From the Nurses' Health Study and Health Professionals Follow-up Study. JAMA Ophthalmol. 2016; 134: 294-303.
5. Lavia C, Dallorto L, Maule M, Ceccarelli M and Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PLoS One. 2017; 12: e0183142.
6. Fea AM, Ahmed, II, Lavia C, et al. Hydrus microstent compared to selective laser trabeculoplasty in primary open angle glaucoma: one year results. Clin Exp Ophthalmol. 2017; 45: 120-7.
7. Gedde S, Feuer W, Shi W, et al. Treatment outcomes in the Primary Tube Versus Trabeculectomy (PTVT) study after 1 year of follow-up. The 27th Annual American Glaucoma Society. Coronado, CA 2017.
8. Ahmed II, Gedde S, Lim S, et al. Surgical complications in the Primary Tube Versus Trabeculectomy (PTVT) study during the first year of follow-up. The 27th Annual American Glaucoma Society Meeting. Coronado, CA 2017.
9. Sng CC, Wang J, Hau S, Htoon HM and Barton K. XEN-45 collagen implant for the treatment of uveitic glaucoma. Clin Exp Ophthalmol. 2017.
10. Prokosch-Willing V, Vossmerbaeumer U, Hoffmann E and Pfeiffer N. Suprachoroidal Bleeding after XEN Gel Implantation. J Glaucoma. 2017.
11. Realini T, Shillingford-Ricketts H, Burt D and Balasubramani GK. West Indies Glaucoma Laser Study (WIGLS): 1. 12-Month Efficacy of Selective Laser Trabeculoplasty in Afro-Caribbeans With Glaucoma. Am J Ophthalmol. 2017; 184: 28-33.
12. De Keyser M, De Belder M, De Belder J and De Groot V. Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients. Acta Ophthalmol. 2017.
13. De Keyser M, De Belder M and De Groot V. Quality of life in glaucoma patients after selective laser trabeculoplasty. Int J Ophthalmol. 2017; 10: 742-8.
14. De Keyser M, De Belder M and De Groot V. Selective laser trabeculoplasty in pseudophakic and phakic eyes: a prospective study. Int J Ophthalmol. 2017; 10: 593-8.
15. Aptel F, Musson C, Zhou T, Lesoin A and Chiquet C. 24-Hour Intraocular Pressure Rhythm in Patients With Untreated Primary Open Angle Glaucoma and Effects of Selective Laser Trabeculoplasty. J Glaucoma. 2017; 26: 272-7.
16. Varma DK, Kletke SN, Rai AS and Ahmed IIK. Proportion of undetected narrow angles or angle closure in cataract surgery referrals. Can J Ophthalmol. 2017; 52: 366-72.
17. Varma DK, Simpson SM, Rai AS and Ahmed IIK. Undetected angle closure in patients with a diagnosis of open-angle glaucoma. Can J Ophthalmol. 2017; 52: 373-8.
18. Vera V, Naqi A, Belovay GW, Varma DK and Ahmed, II. Dysphotopsia after temporal versus superior laser peripheral iridotomy: a prospective randomized paired eye trial. Am J Ophthalmol. 2014; 157: 929-35.
19. Srinivasan K, Zebardast N, Krishnamurthy P, et al. Comparison of New Visual Disturbances after Superior versus Nasal/Temporal Laser Peripheral Iridotomy: A Prospective Randomized Trial. Ophthalmology. 2017.
20. Vijaya L, Asokan R, Panday M and George R. Is prophylactic laser peripheral iridotomy for primary angle closure suspects a risk factor for cataract progression? The Chennai Eye Disease Incidence Study. Br J Ophthalmol. 2017; 101: 665-70.
21. Javanbakht M, Azuara-Blanco A, Burr JM, et al. Early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma: an economic evaluation based on data from the EAGLE trial. BMJ Open. 2017; 7: e013254.
22. Emanuel ME, Grover DS, Fellman RL, et al. Micropulse Cyclophotocoagulation: Initial Results in Refractory Glaucoma. J Glaucoma. 2017; 26: 726-9.
23. Anderson AJ, Bedggood PA, George Kong YX, Martin KR and Vingrys AJ. Can Home Monitoring Allow Earlier Detection of Rapid Visual Field Progression in Glaucoma? Ophthalmology. 2017; 124: 1735-42.
24. Schulz AM, Graham EC, You Y, Klistorner A and Graham SL. Performance of iPad-based threshold perimetry in glaucoma and controls. Clin Exp Ophthalmol. 2017.
25. De Moraes CG, Hood DC, Thenappan A, et al. 24-2 Visual Fields Miss Central Defects Shown on 10-2 Tests in Glaucoma Suspects, Ocular Hypertensives, and Early Glaucoma. Ophthalmology. 2017; 124: 1449-56.
26. Jung Y, Park HL, Park YR and Park CK. Usefulness of 10-2 Matrix Frequency Doubling Technology Perimetry for Detecting Central Visual Field Defects in Preperimetric Glaucoma Patients. Sci Rep. 2017; 7: 14622.
27. Roberti G, Manni G, Riva I, et al. Detection of central visual field defects in early glaucomatous eyes: Comparison of Humphrey and Octopus perimetry. PLoS One. 2017; 12: e0186793.
28. Blumberg DM, De Moraes CG, Prager AJ, et al. Association Between Undetected 10-2 Visual Field Damage and Vision-Related Quality of Life in Patients With Glaucoma. JAMA Ophthalmol. 2017; 135: 742-7.
29. Wu Z, Saunders LJ, Daga FB, Diniz-Filho A and Medeiros FA. Frequency of Testing to Detect Visual Field Progression Derived Using a Longitudinal Cohort of Glaucoma Patients. Ophthalmology. 2017; 124: 786-92.
30. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385: 1295-304.
31. Shoji T, Zangwill LM, Akagi T, et al. Progressive Macula Vessel Density Loss in Primary Open-Angle Glaucoma: A Longitudinal Study. Am J Ophthalmol. 2017; 182: 107-17.
32. Chen HS, Liu CH, Wu WC, Tseng HJ and Lee YS. Optical Coherence Tomography Angiography of the Superficial Microvasculature in the Macular and Peripapillary Areas in Glaucomatous and Healthy Eyes. Invest Ophthalmol Vis Sci. 2017; 58: 3637-45.
33. Triolo G, Rabiolo A, Shemonski ND, et al. Optical Coherence Tomography Angiography Macular and Peripapillary Vessel Perfusion Density in Healthy Subjects, Glaucoma Suspects, and Glaucoma Patients. Invest Ophthalmol Vis Sci. 2017; 58: 5713-22.
34. Shin JW, Sung KR, Lee GC, Durbin MK and Cheng D. Ganglion Cell-Inner Plexiform Layer Change Detected by Optical Coherence Tomography Indicates Progression in Advanced Glaucoma. Ophthalmology. 2017; 124: 1466-74.
35. Bowd C, Zangwill LM, Weinreb RN, Medeiros FA and Belghith A. Estimating Optical Coherence Tomography Structural Measurement Floors to Improve Detection of Progression in Advanced Glaucoma. Am J Ophthalmol. 2017; 175: 37-44.
36. De Moraes CG, Susanna R, Jr., Sakata LM and Hatanaka M. Predictive Value of the Water Drinking Test and the Risk of Glaucomatous Visual Field Progression. J Glaucoma. 2017; 26: 767-73.
37. Kim J, Park DY, Bae H, et al. Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma. J Clin Invest. 2017; 127: 3877-96.
38. Perez-de-Arcelus M, Toledo E, Martinez-Gonzalez MA, Martin-Calvo N, Fernandez-Montero A and Moreno-Montanes J. Smoking and incidence of glaucoma: The SUN Cohort. Medicine (Baltimore). 2017; 96: e5761.
39. Chan TCW, Bala C, Siu A, Wan F and White A. Risk Factors for Rapid Glaucoma Disease Progression. Am J Ophthalmol. 2017; 180: 151-7.
40. Kuo YS, Liu CJ, Cheng HC, Chen MJ, Chen WT and Ko YC. Impact of socioeconomic status on vision-related quality of life in primary open-angle glaucoma. Eye (Lond). 2017; 31: 1480-7.
  • Hydrus Microstent
  • Xen Gel Implant
  • Cypass Micro-stent (left) and iStent Injection System

' there seems to be an increasing role for dietary and nutritional supplementation in preventing glaucoma and/or halting progression '